Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Claim 1 (Currently amended): A composition comprising tiotropium, or a pharmaceutically acceptable salt or hydrate thereof, an <u>hydrofluorocarbon (HFC)</u> propellant, a solvent, and an acid selected from the group consisting of one or more of inorganic and <u>or</u> organic acid[[s]], wherein the acid has a concentration in a range that corresponds to having a pH range of 2.5 - 4.5 in aqueous solution.

Claim 2 (Currently amended): The composition according to claim 1 comprising 0.00008 to $0.4 \% (\underline{w/w})$ by weight tiotropium, or a pharmaceutically acceptable salt or hydrate thereof.

Claim 3 (Original): The composition according to claim 2, wherein the pharmaceutically acceptable salt of tiotropium is selected from the group consisting of one or more of chloride, bromide, iodide, methanesulphonate or para-toluenesulphonate.

Claim 4 (Original): The composition according to claim 1 wherein the HFC propellant is selected from the group consisting of HFC-134(a), HFC-227, HFC-32, HFC-143(a), HFC-134, HFC-152a, and mixtures thereof.

Claim 5 (Currently amended): The composition according to claim 1 wherein the <u>inorganic</u> acid is selected from the group of inorganic acids consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.

Claim 6 (Currently amended): The composition according to claim 1 wherein the <u>organic</u> acid is selected from the group of organic acids consisting of ascorbic acid, citric acid, lactic acid, malic acid, benzoic acid, and tartaric acid.

Claim 7 (Currently amended): The composition according to claim 1 further comprising water in an amount of up to about 5% (w/w) by weight.

Claim 8 (Currently amended): The composition according to claim 1 wherein the solvent is selected from the group consisting of one or more of alcohols, glycols, glycol ethers, block copolymers of oxyethylene and oxypropylene, glycerol, polyoxyethylene alcohols, polyoxyethylene polyoxyethylene fatty acid esters and glycofurols.

Claim 9 (Currently amended): The composition according to claim 8 wherein the solvent is present in an amount in the range of 5 - 50% (w/w) by weight.

Claim 10 (Currently amended): The composition according to claim 1, wherein the tiotropium is comprising an anhydrous crystalline form of tiotropium bromide.

Claim 11 (Original): The composition according to claim 1 that is free of water.

Claim 12 (Original): The composition according to claim 10 that is free of water.

Claim 13 (Currently amended): The composition according to claim 2 comprising tiotropium bromide monohydrate in a range of from 0.0001% to 0.5% (w/w) (by weight), ethanol in the range of 5% to 50% (w/w) (by weight), water up to 5% (w/w) (by weight), acid in an amount to yield a pH range of 2.5 to 4.5 in aqueous solution, and an HFC propellant.

Claim 14 (Currently amended): The composition according to claim 10 comprising anhydrous crystalline tiotropium bromide in the range of 0.0001% to 0.5% (w/w) (by weight), ethanol in the range of 5% to 50% (w/w) (by weight), water up to 5% (w/w) (by weight), acid in an amount to yield a pH range of 2.5 to 4.5 in aqueous solution, and an HFC propellant.

Claim 15 (Original): A device for the administration of aerosol compositions comprising the composition according to claim 1.

Claim 16 (Original): A device for the administration of aerosol compositions comprising the composition according to claim 10.

Claim 17 (Original): A device for the administration of aerosol compositions comprising the composition according to claim 13.

Claim 18 (Original): A device for the administration of aerosol compositions comprising the composition according to claim 14.

Claim 19 (Original): The device according to claim 15 in the form of a metered-dose inhaler.

Claim 20 (Original): The composition according to claim 1 in the form of an aerosol solution formulation.